Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Summary

The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.

Timeline

Start

2016-08-01

Primary completion

2017-04-28

Completion

2017-05-22

Outcome

Outcome not reported

Stopped: “Lack of Efficacy”

Drugs

Indications